 Study entry requires a diagnosis of low or intermediate INT-1 risk MDS per International Prognostic Scoring System IPSS criteria and serum ferritin 1000 ngmL. Patients must have had at least 30 prior red blood cell transfusions. Deferasirox will be administered at an initial dose of 20 mgkg orally once per day. Patient transfusion history and at least three complete blood count CBC values must be available for the 12 weeks prior to study registration for patients with MDS and chronic iron overload from blood transfusions. 